MGC Pharmaceuticals Reports Increase in Prescription Above 1,800

  • Dec 17, 2019 AEDT
  • Team Kalkine

MGC Pharmaceuticals Ltd (ASX: MXC) announced that it has reached more than 1,800 prescriptions of its standardised, affordable cannabinoid medicines, achieved from patients in Australia, the UK and with the latest additions of new patient special access approved markets of Brazil & Ireland after the recent consent for the sale of CannEpil® in these nations.

Apart from this, the company has also received its first purchase order from Brazil under its contract with ONIX Empreendimentos e Participações which at present is being manufactured and is anticipated to be shipped by December 2019 end.

AT AEDT: 1:30 PM, MXC shares are trading at $0.032, up 6.667% from its previous close.


All pictures are copyright to their respective owner(s) does not claim ownership of any of the pictures displayed on this website unless stated otherwise. Some of the images used on this website are taken from the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image.


There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.

Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.

As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK